替瑞奇珠单抗与司库奇尤单抗治疗中重度斑块状银屑病的疗效和安全性对比 点击下载
| 论文标题： | 替瑞奇珠单抗与司库奇尤单抗治疗中重度斑块状银屑病的疗效和安全性对比 |
| 英文标题： | |
| 中文摘要： | 目的 比较替瑞奇珠单抗与司库奇尤单抗治疗中重度斑块状银屑病的有效性及安全性。方法回顾性分析2024年1月至2025年4月在南阳医学高等专科学校第一附属医院接受治疗的141例中重度斑块状银屑病患者，根据治疗方案分为替瑞奇珠单抗组（61例）和司库奇尤单抗组（80例）。比较两组患者PASI75、PASI90、PASI100达标率，治疗前后银屑病面积与严重程度指数（PASI）和皮肤病生活质量指数（DLQI）评分、皮肤屏障功能（皮脂含量、角质层含水量）、炎症因子[白细胞介素17（IL-17）、肿瘤坏死因子α（TNF-α）、IL-23]水平，以及治疗期间不良反应发生率。结果经过12周治疗后，替瑞奇珠单抗组患者的PASI75、PASI90及PASI100达标率均显著高于司库奇尤单抗组（P＜0.05）。治疗后，两组患者的PASI、DLQI评分以及IL-17、TNF-α、IL-23水平均较同组治疗前显著降低，皮脂含量和角质层含水量均较同组治疗前显著升高（P＜0.05），且替瑞奇珠单抗组均优于司库奇尤单抗组（P＜0.05）。替瑞奇珠单抗组患者的总体不良反应发生率显著低于司库奇尤单抗组（P＜0.05）。结论与司库奇尤单抗相比，替瑞奇珠单抗治疗中重度斑块状银屑病的疗效更优，在改善症状、提升皮肤屏障功能、降低炎症因子水平方面效果更显著，且安全性更好。 |
| 英文摘要： | OBJECTIVE To compare the efficacy and safety of tildrakizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis. METHODS A retrospective analysis was conducted on 141 patients with moderate-to-severe plaque psoriasis treated at the First Affiliated Hospital of Nanyang Medical College from January 2024 to April 2025. According to the treatment regimen，the patients were divided into tildrakizumab g roup （ n ＝61） and secukinumab group （ n ＝80）. The PASI 75，PASI 90，and PASI 100 response rates， the Psoriasis Area and Severity Index （PASI） and Dermatology Life Quality Index （DLQI） scores， skin barrier function （sebum content and stratum corneum water content）， inflammatory factor levels [interleukin-17 （IL-17）， tumor necrosis factor-α （TNF-α）， and IL-23 ] before and after treatment， and the incidence of adverse drug reactions during treatment were compared between the two groups. RESULTS After 12 weeks of treatment， the PASI 75， PASI 90， and PASI 100 response rates in the tildrakizumab group were significantly higher than those in the secukinumab group （ P ＜0.05）. After treatment， PASI and DLQI scores as well as serum levels of IL-17， TNF-α， and IL-23 in both groups were significantly reduced compared to before treatment in the same group； sebum content and stratum corneum water content were significantly increased compared to before treatment in the same group （ P ＜0.05）； the tildrakizumab group showed better results than the secukinumab group （ P ＜0.05）. The overall incidence of adverse drug reactions was also significantly lower in the tildrakizumab group compared with the secukinumab group （ P ＜0.05）. CONCLUSIONS Compared with secukinumab， tildrakizumab demonstrates superior efficacy in the treatment of moderate-to-severe plaque psoriasis， providing improved symptom relief， enhanced skin barrier function， reduced levels of inflammatory factors， and higher safety. |
| 期刊： | 2026年第37卷第07期 |
| 作者： | 陈宁；冯要菊；丁昱 |
| 英文作者： | CHEN Ning，FENG Yaoju，DING Yu |
| 关键字： | 替瑞奇珠单抗；司库奇尤单抗；中重度斑块状银屑病；有效性；安全性；生物制剂 |
| KEYWORDS： | tildrakizumab； secukinumab； moderate-to-severe plaque psoriasis； efficacy； safety； biological agent |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！